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AF = activation function domain; CBP = CREB-binding protein; E6-AP = E6-associated protein; ER = estrogen receptor; N-CoR = nuclear recep-
tor corepressor; PR = progesterone receptor; RPF1 = receptor potentiation factor-1; RTA = repressor of tamoxifen transcriptional activity; SMRT =
silencing mediator of retinoid and thyroid receptor; SRA = steroid receptor RNA activator; SRC = steroid receptor coactivator; Uba3 = ubiquitin-
activating enzyme.
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Introduction
The progesterone receptor (PR) is a member of the
nuclear receptor superfamily, which specifically regulates
the expression of target genes in response to the hor-
monal stimulus. In the absence of progesterone, the PR is
sequestered in a nonproductive form associated with heat
shock proteins and other cellular chaperones. In this state,
the PR is considered unable to influence the rate of trans-
cription of its cognate promoters [1]. On binding with
progesterone, the PR undergoes a series of events,
including conformational changes, dissociation from heat
shock protein complexes, dimerization, phosphorylation,
and nuclear translocation, which enables its binding to
progesterone-response elements within the regulatory
regions of target genes. The binding of PR to the proges-
terone-response elements is followed by the recruitment
of coactivators and the basal transcription machinery,
leading to the upregulation of target gene transcription.
The PR exists as two isoforms in most rodents and
humans, PR-A and PR-B, which are produced from a
single gene by translation initiation at two distinct start
codons under the control of separate promoters [2]. The
difference between PR-A and PR-B is that PR-A is a trun-
cated form of PR-B. In humans, the N-terminal 164 amino
acids of PR-B are missing in isoform PR-A. Detailed mole-
cular dissection has identified two distinct activation func-
tion domains (AFs) within both PRs: AF-1, which is
located in the N-terminal region, is ligand independent;
AF-2, which is ligand dependent, is contained in the
ligand-binding domain that is located in the C-terminal
region. A DNA-binding domain and the hinge region are
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mapped to the central region of both receptors. Further-
more, a unique activation function domain, AF-3, is con-
tained in the upstream segment of PR-B that is missing in
PR-A (Fig. 1).
Progesterone and estrogen are essential regulators of
female reproductive activity. Through their cognate recep-
tors, estrogen and progesterone regulate the normal devel-
opment of the ovary, the uterus and the mammary gland,
and play key roles in the tumorigenesis of these tissues. It
has been demonstrated by estrogen receptor (ER) and PR
knockout mice that estrogen controls the early ductal mor-
phogenesis of the mammary gland, whereas progesterone
controls ductal branching and alveolar development of the
mammary gland during pregnancy [3].
Although the two forms of the PR have similar structures
and are identical in DNA and ligand binding, in vitro
studies using a reconstituted progesterone-responsive
transcription system in mammalian cells revealed that
PR-A and PR-B are not functionally identical. In most
cases, PR-B acts as a potent activator of transcription of
target genes, whereas PR-A acts as a dominant repressor
of transcription of PR-B as well as a few other nuclear
receptors [4]. The AF-3 domain in PR-B is partially respon-
sible for the higher transcriptional activity of PR-B relative
to PR-A. Moreover, an inhibitory function domain that is
located in the N-terminus of both receptor isoforms has
been identified [2]. This inhibition function domain can
inhibit the activity of AF-1 and AF-2 but not that of AF-3,
which explains why PR-B is a potent activator of transcrip-
tion. The inhibition function domain is functionally indepen-
dent and is transferable; when placed upstream of the ER,
the inhibition function domain can also suppress ER activity.
The relative expression of PR-A and PR-B in the target
tissues is dependent on species, cellular context, and the
physiological and hormonal status. The ratio of PR-A to
PR-B in specific tissues or cell types defines the physio-
logical and pharmacological responses to progesterone.
In the mammary gland, the ratios of PR-A to PR-B are con-
stant from puberty to pregnancy, although there are
species differences [5]. From PR-A knockout mice, it has
been demonstrated that PR-B is mainly responsible for the
normal proliferative and differentiative responses of the
mammary gland to progesterone, because PR-A knockout
mice exhibit a similar phenotype to PR knockout mice [3].
Overexpression of PR-A over PR-B in transgenic mice
results in extensive epithelial cell hyperplasia, in excessive
ductal branching, and in a disorganized basement mem-
brane. All these features are associated with neoplasia [6].
Furthermore, the development of the mammary gland in
PR-B overexpressed transgenic mice is also abnormal [7],
indicating that a regulated expression of PR-A and PR-B
and the native ratios of the two isoforms are critical to the
appropriate responsiveness of the mammary gland to
progesterone. Consistent with the findings from animal
studies, very low levels of PR-B and a consequently high
PR-A:PR-B ratio were found in a significant proportion of
human breast cancer samples [8]. Taking these findings
together, it can be inferred that imbalance of PR-A versus
PR-B may be associated with the development, progres-
sion or prognosis of breast cancer.
Coactivators are factors that can interact with nuclear
receptors in a ligand-dependent manner and enhance
their transcriptional activity. Corepressors are factors that
interact with nuclear receptors and repress their tran-
scriptional activity. Both types of coregulators are
required for efficient modulation of target gene transcrip-
tion by the PR [9]. Changes in the expression level and
pattern of PR coactivators or corepressors, or mutation of
their function domains, might therefore affect the tran-
scriptional activity of the PR and hence cause disorders
of its target tissues, including the mammary gland. The
present review will describe the coactivators and core-
pressors that are involved in the transcriptional modula-
tion of PRs, with emphasis on their roles in breast cancer
development and progression.
Progesterone receptor coactivators
The steroid receptor coactivator family
The steroid receptor coactivator (SRC) family is composed
of three distinct but structurally and functionally related
members: SRC-1 (nuclear receptor coactivator 1), SRC-2
(transcription intermediary factor 2/glucocorticoid recep-
tor-interacting protein 1/nuclear receptor coactivator 2),
and SRC-3 (p300/CREB-binding protein [CBP] cointe-
grator-associated protein/receptor-associated coactivator
3/activator of thyroid and retinoid receptors/amplified in
breast cancer 1/thyroid receptor activator molecule 1).
SRC-1 was the first identified coactivator for the steroid
receptor superfamily, which was cloned and characterized
in 1995 [10]. SRC-2 and SRC-3 were then identified
thereafter by several laboratories [9].
Sequence analysis of SRC proteins identified a basic
helix–loop–helix domain and two Per–Arnt–Sim domains
in the amino-terminal region. The basic helix–loop–helix/
Figure 1
Schematic representation of the progesterone receptor PR-A and PR-
B proteins. The DNA-binding domain (DBD), the ligand-binding domain
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Per–Arnt–Sim domain is highly conserved among the
SRC members, and it serves as a DNA binding and
protein dimerization motif in many transcription factors
[11]. Following the basic helix–loop–helix/Per–Arnt–Sim
domain, there are a centrally located receptor-interacting
domain and a C-terminal transcriptional activation domain.
Detailed analysis revealed three conserved LXXLL motifs
(nuclear receptor box) in the receptor-interacting domain,
which appear to contribute to the specificity of coactivator–
receptor interaction. Histone acetyltransferase activity was
identified in the C-terminal region of SRC members, and
there also exist activation domains that can interact with
the CBP.
All three members of the SRC family interact with the PR
and enhance its transcriptional activation in a ligand-depen-
dent manner [12,13]. Targeted deletion of the SRC-1 gene
in mice has indicated that SRC-1 is important for the bio-
logical actions of progesterone in mammary gland devel-
opment since the hormone-induced ductal elongation and
alveolar development is greatly impaired in the null mice
[14]. In the meantime, the expression of SRC-2 mRNA
was elevated in SRC-1 null mice, suggesting that SRC-2
can partially compensate for SRC-1 function [14].
SRC-3 is the most distinct among the three members. It
coactivates not only the nuclear receptors, but also other
unrelated transcription factors such as those in the
cAMP or cytokine pathways [15]. Compared with the
widespread expression of SRC-1 and SRC-2, expres-
sion of SRC-3 is restricted to the mammary gland and
several other tissues [16]. Disruption of the SRC-3 gene
in mice causes severe growth and reproductive defects,
including the retardation of mammary gland development
[17]. Furthermore, amplification and overexpression of
SRC-3 were observed in 10% and 64% of human
primary breast cancers, respectively [18]. This observa-
tion indicates that SRC-3 is not only essential for the
normal mammary development, but also plays a role in
breast tumorigenesis.
E6-associated protein/RPF1
E6-associated protein (E6-AP) and RPF1, the human
homolog of yeast RSP5, are E3 ubiquitin-protein ligases
that target proteins for degradation by the ubiquitin
pathway. They are also characterized as coactivators of
steroid receptors. It has been demonstrated by transient
transfection assay that RPF1 and E6-AP could potentiate
the ligand-dependent transcriptional activity of the PR, the
glucocorticoid receptor, and other nuclear receptors
[19,20]. Furthermore, RPF1 and E6-AP acted synergisti-
cally to enhance PR transactivation [20]. Additionally, the
coactivation functions of E6-AP and RPF1 are separable
from the E3 ubiquitin-protein ligase activity, as ubiquitin
ligase-defective E6-AP and RPF1 exhibited normal coacti-
vation function.
E6-AP is expressed in many tissues, including the
mammary gland. From its ability to coactivate the PR and
the ER in a hormone-dependent manner, it was assumed
that E6-AP is an essential regulator for the development of
normal mammary gland and mammary tumors. The first
evidence of a relationship between E6-AP and breast
cancers was obtained from the study of a spontaneous
mouse mammary tumorigenesis model, which demon-
strated that E6-AP was overexpressed in tumors when
compared with normal tissues [21].
We recently examined the expression pattern of E6-AP in
biopsy samples of human breast cancers, and our results
showed that E6-AP expression was decreased in tumors
in comparison with the adjacent normal tissues (Gao et al.,
unpublished data, 2002). Furthermore, we demonstrated
that the decreased expression of E6-AP was stage depen-
dent, and that the expression of E6-AP was inversely cor-
related with that of the ER in breast tumors. Since the ER
plays a major role in breast cancer development and the
PR is a target of estrogen, the changes of the expression
level of E6-AP might interfere with the normal functioning
of the ER and the PR. Hence, E6-AP may participate in
the formation and progression of breast tumors.
Steroid receptor RNA activator
The growing family of nuclear receptor coactivators has
recently acquired a unique member, steroid receptor RNA
activator (SRA) [22]. Differing from the other coactivators,
SRA functions as a RNA transcript instead of as a protein.
SRA specifically coactivates the transcriptional activity of
steroid receptors, including the PR, the ER, the glucocorti-
coid receptor, and the androgen receptor. It has been
demonstrated that SRA exists in a ribonucleoprotein complex
containing SRC-1 and that it mediates transactivation through
the AF-1 domain located at the N-terminal region of nuclear
receptors, distinguishing it from the other coactivators.
SRA is expressed in normal and malignant human
mammary tissues [23,24]. An elevated expression of SRA
was found in tumors compared with the adjacent normal
region [24]. Although it is currently unknown whether the
expression of SRA is correlated with that of the PR or the
ER, the increase in the SRA levels in tumor cells may con-
tribute to the altered ER/PR action that is known to occur
during breast tumorigenesis.
L7/SPA
L7/SPA is a 27 kDa protein containing a basic leucine
zipper domain. L7/SPA is an antagonist-specific transcrip-
tional coactivator because it can only potentiate the partial
agonist activity of some antagonists, including tamoxifen
and RU486, but has no effect on the agonist-mediated
transcription [25]. This unique property of L7/SPA sug-
gests that it might play a role in the development of resis-
tance to hormone therapy for breast cancers.185
CBP/p300
CBP was initially characterized as a coactivator required
for efficient transactivation of cAMP-response element-
binding protein, and p300 was first identified as a coacti-
vator of the adenovirus E1A oncoprotein. CBP and p300
share many functional properties: both of them function as
coactivators for multiple nuclear receptors as well as p53
and nuclear factor-κB [9], both possess intrinsic histone
acetyltransferase activity, and both can recruit histone
acetyltransferase and CBP/p300-associated factor [26].
Besides, CBP/p300 interacts with members of the SRC
family and synergizes with SRC-1 in the transactivation of
the ER and the PR [27].
Other coactivators
In addition to the coactivators already discussed, there are a
few other proteins that have been demonstrated to upregu-
late the transcriptional activity of the PR. Chromatin high-
mobility group protein 1, chromatin high-mobility group
protein 2, TIP60 (Tat-interacting protein), proline-rich
nuclear receptor coregulatory protein 1, proline-rich nuclear
receptor coregulatory protein 2, Cdc25B, and GT198 all
function as PR coactivators, as demonstrated by transient
transfection assays [28–32]. Cdc25B is prominent among
these coactivators in terms of its roles in breast cancer
development, because Cdc25B transgenic mice exhibit
mammary gland hyperplasia and increased steroid hormone
responsiveness [31]. The significance of all these coactiva-
tors in vivo needs to be further investigated.
Progesterone receptor corepressors
Nuclear receptor corepressor/silencing mediator of
retinoid and thyroid receptors
Nuclear receptor corepressor (N-CoR) and silencing
mediator of retinoid and thyroid receptor (SMRT) are both
corepressors of numerous transcription factors, including
steroid hormone receptors. Both N-CoR and SMRT
interact with the nuclear receptors through the receptor-
interacting domains located in the C-terminal portion of
the proteins, while their transcriptional repression domains
are mapped to the N-termini [33]. N-CoR and SMRT also
associate with HDAC3 in large protein complexes, which
is an important pathway for transcriptional repression.
Corepressors N-CoR and SMRT interact with the nuclear
receptors either in the absence of agonists (in the case of
the thyroid receptor and the retinoid acid receptor) or in
the presence of antagonists (in the case of steroid recep-
tors) [33]. Since N-CoR and SMRT are common co-
repressors for transcription factors, slight alteration of their
expression level in certain tissues might result in signifi-
cant transcriptional changes, leading to altered develop-
ment of the mammary gland, even tumors.
BRCA1
BRCA1 is a breast cancer susceptibility gene, and its
inherited mutations are correlated with an increased risk of
breast cancer and ovarian cancer [34]. The role of
BRCA1 in cancer development is unclear. In addition to
its ability to coactivate p53 and to modulate p300/CBP
expression,  BRCA1 is also a ligand-independent co-
repressor for the ER, the androgen receptor and the PR
[35]. If BRCA1 is mutated, all of these pathways will be
more or less impaired. The effect of BRCA1 in cancer
development might therefore be multiplex.
Other corepressors
Ubiquitin-activating enzyme 3 (Uba3) is the catalytic
subunit of the activating enzyme in the ubiquitin-like
NEDD8 (neural precursor cell-expressed developmentally
downregulated) conjugation (neddylation) pathway. Uba3
was recently demonstrated as a corepressor of the ER,
the androgen receptor and the PR in mammalian transfec-
tion assays [36]. Uba3 inhibited the transactivation of the
ER in a time-dependent manner, and neddylation activity
of Uba3 is required for this suppression. This suggests
that Uba3 suppresses steroid receptor activity by promot-
ing the termination of receptor-mediated gene transcrip-
tion rather than by interfering with the initial events.
Repressor of tamoxifen transcriptional activity (RTA) has
recently been defined as a potent repressor of tamoxifen-
mediated ERα transcriptional activity as well as an agonist
of the ERβ, the glucocorticoid receptor, and the PR [37].
The interaction of RTA with the nuclear receptors requires
the participation of RNA, because mutation of the RNA
recognition motif in RTA compromises its ability to repress
transcription [37].
The roles of Uba3 and RTA in mammary gland develop-
ment and tumorigenesis await further study.
Summary
As a transcription factor, the PR activates target gene tran-
scription in response to the hormonal stimulus, and its
functions are modulated by coactivators and corepressors.
Different coregulators exert their actions through different
mechanisms, and involvement in the development of
normal mammary gland and the formation or progression of
tumors has been reported in some coactivators and some
corepressors. The coactivators and corepressors of the PR
so far identified are not PR specific, since they can also
modulate the transactivation of many other nuclear recep-
tors. In addition, no unique coregulators of PR-A or PR-B
have been identified. Identification of PR-specific coregula-
tory proteins, especially PR-A interacting factors or PR-B
interacting factors, is an important goal of future study.
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